Introduction
A construct that silences or expresses a target in cells is not yet a medicine. The distance is made of lipid choice, impurity control, innate-immune readouts and a regulatory file that can survive a second pair of eyes.
Discussion
Formulation
Ionisable lipids, helper lipids and PEG density are not interchangeable decorations. Papers that omit molar ratios, mixing geometry and storage conditions cannot be compared with one another.
Safety and regulation
Innate-immune activation, complement and off-target editing sit on the critical path. A review that lists approved products without the toxicology that preceded them is a catalogue, not a translational map.
Conclusion
The useful RNA paper states the formulation, the safety endpoint and the regulatory question in the same document. That is the standard this sample review is written to illustrate.